CURRICULUM VITAE
Mary Sorci Thomas PhD
Mary Sorci Thomas PhD
Professor
Department of Medicine
Division of Endocrinology
Department of Medicine
Division of Endocrinology
OFFICE ADDRESS: |
Health Research Center |
8701 Watertown Plank Rd |
Milwaukee, WI 53226 |
EDUCATION: |
- 1979 BS, Louisiana State University, Baton Rouge, LA |
- 1984 PhD, Wake Forest University School of Medicine, Winston-Salem, NC |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
12/1984 - 04/1987 Postdoctoral Fellow, Department of Pharmacological Sciences, State University of New York, Stony Brook, NY |
FACULTY APPOINTMENTS: |
1976 - 1979 Research Technician/Freshman Lab Instructor, Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana, LA |
1987 - 1988 Instructor, Department of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC |
1988 - 1984 Assistant Professor, Department of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC |
1989 - Present Associate in the Department of Biochemistry, Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC |
1994 - 2002 Associate Professor, Department of Pathology Section of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC |
2002 - Present Professor with Tenure, Department of Pathology Section on Lipid Sciences, Wake Forest University School of Medicine, Winston-Salem, NC |
2014 - Present Professor with Tenure, Department of Medicine, Division of Endocrinology, Metabolism and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, WI |
2014 - Present Adjunct Investigator, Blood Research Institute, Milwaukee, WI |
ADMINISTRATIVE APPOINTMENTS: |
2002 - 2007 Reviewer, Pfizer International HDL Awards 2002-2007 |
2019 - Present Associate Director, Cardiovascular Center, Medical College of Wisconsin |
EDUCATIONAL ADMINISTRATIVE APPOINTMENTS: |
2019 - Present Associate Program Director, CVC T32 Training Program, Medical College of Wisconsin |
RESEARCH ADMINISTRATIVE APPOINTMENTS: |
1976 - 1979 Research Technician/Freshman Lab Instructor, Department of Chemistry, Louisiana State University, Baton Rouge, LA |
2014 - 2015 Senior Adjunct Investigator, Versiti Blood Research Institute |
2014 - 2015 Associate, Pharmacology and Toxicology, Medical College of Wisconsin |
AWARDS AND HONORS: |
01/1983 - 12/1984 R.J. Reynolds Special Fellow, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC |
07/1983 - 07/1984 Recipient, North Carolina Affiliate Pre-doctoral, Grant-in-Aid, American Heart Association |
05/1984 Recipient, Sigma Xi Graduate Research Award in Biomedical Research |
12/1984 - 12/1986 Recipient, National Research Service Award Postdoctoral Fellowship, National Institutes of Health |
11/1991 Finalist, Louis N. Katz Basic Science Research Prize for Young Investigators, American Heart Association |
07/1994 - 06/1999 Established Investigator, American Heart Association |
04/06/2002 Recipient, Second Annual Women’s Mentoring Award, American Heart Association, The Women’s Leadership Committee |
06/22/2002 Elected Co-Chair for 2004 and Chair for 2006 Gordon Conference on Lipoprotein Metabolism, Conference on Lipoprotein Metabolism |
11/19/2002 Special Recognition Award, Arteriosclerosis, Thrombosis and Vascular Biology Council of the American Heart Association, Chicago, IL |
09/2004 - 2011 Kern Aspen Lipid Conference Board |
08/22/2010 - Present Chair , Kern Aspen Lipid Meeting |
03/09/2015 - Present Texas A&M Keynote Speaker for the Nutritional Graduate Student Association Symposium |
12/21/2016 - Present External Advisory Board Columbia University T32 Training Grant |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
American Association for the Advancement of Science |
Fellow of the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association |
New York Academy of Science |
American Society for Biochemistry and Molecular Biology |
Society of Sigma Xi |
Iota Sigma Pi |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Journal Review |
1998 - 2010 Journal of Lipid Research |
2008 - Present Arteriosclerosis, Thrombosis, and Vascular Biology |
2013 - Present Journal of Lipid Research |
PLoS ONE |
Atherosclerosis |
Circulation Research |
Atherosclerosis, Thrombosis, and Vascular Biology |
Journal of Biological Chemistry |
American Journal of Pathology |
Circulation |
Nature |
Journal Clinical Investigation |
Protein Sciences |
Biochimica et Biophysica Acta |
Biochemistry |
Ad-Hoc Reviewer |
1992 - 1994 NIH, NHLBI, Metabolism Study Section |
1992 - 1994 Special Emphasis Panel on the use of Transgenic Animals in Biomedical Research |
1999 NIH, NIA, Program Project Review Committee |
2000 - Present NIH, NHLBI, Program Project Review Committee |
2003 NIH, NHLBI, Metabolism Study Section |
2004 - 2005 NIH, NHLBI, Integrated Nutrition and Metabolic Pathways Study Section, |
2004 - 2008 NIH, NHLBI, Atherosclerosis, Inflammation and Cardiovascular Science Study Section |
2013 - Present NIH, NHLBI, Vascular Cell and Molecular Biology (VCMB) Study Section |
2013 - 2014 NIH, NHLBI, Atherosclerosis, Inflammation and Cardiovascular Systems (AICS) Study Section |
2014 - Present NIH NHLBI Program Project Review Committee |
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
1989 - 1992 Research Review Subcommittee, AHA N.C. Affiliate, American Heart Association, North Carolina Affiliate |
1991 - 2012 Interviewer, Wake Forest University Medical School Admissions, Wake Forest University Medical School |
1991 - 1992 Treasurer, Society of Sigma Xi Wake Forest University Chapter, Wake Forest University Graduate School |
1992 - 1995 Member, Standing Committee on Nutrition, National American Heart Association |
1992 - 1995 Member, Wake Forest University Intramural Research Support Committee, Wake Forest University Graduate School |
1992 - 1993 Vice President, Society of Sigma Xi Wake Forest University Chapter, Wake Forest University Graduate School |
1992 - 1995 Abstract Grading Consultant, Abstract Grading Consultant, National American Heart Association Scientific Meetings Categories on Arteriosclersosis |
1992 - 1995 Board of Directors, AHA N.C. Affiliate, American Heart Association, North Carolina Affiliate |
1992 - 1995 Research Committee, AHA N.C. Affiliate, American Heart Association, North Carolina Affiliate |
1992 - 1999 Co-Chairman of High School Student Research Program, AHA N.C. Affiliate, American Heart Association, North Carolina Affiliate |
1992 Co-chair, Scientific Session on “Apoprotein Gene Expression”, 65th Scientific Session National American Heart Association Meeting |
1993 - 1995 Abstract Grading Consultant, National American Heart Association Scientific Meetings Categories on Nutrition |
1993 - 1995 Transgenic Mouse Facility Planning Committee, Wake Forest University Graduate School |
1993 - 1994 President, Society of Sigma Xi Wake Forest University Chapter, Wake Forest University Graduate School |
1993 - 1995 Member, Credentials Committee, National Heart Association |
1994 - 1997 Dean's Advisory Committee, Wake Forest University Medical School |
1994 - 1998 Executive Committee, Council on Arteriosclerosis, AHA |
1994 - 2000 Graduate Council Representative, Wake Forest University, Wake Forest University Graduate School |
1994 Administrative Infrastructure Review Working Group, Wake Forest University Graduate School |
1994 - 1998 Chair, Women and Minorities Leadership Committee, American Heart Association, Council on Arteriosclerosis |
1996 - 2000 Member, Program Project Review Committee, NIH, NHLBI |
1997 Co-Chair, Scientific Session on “HDL Metabolism and Gender”, 70th Scientific Sessions of the National American Heart Association Meeting, Orlando Florida, 1997 |
1997 - 2014 Seminar Director, Molecular and Cellular Pathobiology Program, Wake Forest University Graduate School |
09/10/1998 - 09/13/1998 Co-Chair, Workshop on “HDL/ApoA-I Structure:Function”, th Annual Southeast Lipid Conference, Lake Lanier, GA |
1998 - 2005 Committee on Wake Forest University Medical School Admissions, Wake Forest University Medical School |
1998 Co-Chair, Scientific Session on “HDL Structure:Function”, 71st Scientific Sessions, American Heart Association Meeting, Dallas, Texas |
1998 Panelist, 2nd Annual Forum on Graduate Education 1998, “Mentoring, Tends and Models”, sponsored by the Graduate School of Arts and Sciences, Wake Forest University, Wake Forest University Graduate School |
09/09/1999 - 09/12/1999 Co-Chair, Session on Lipoprotein Biosynthesis and Metabolism I, 8th Southeastern Lipid Conference, Lake Lanier, GA |
1999 Co-Chair, Scientific Session on “Lipoprotein Metabolism and Atherosclerosis in Transgenic and Knockout Models“, 72rd Scientific Session, American Heart Association Meeting, Atlanta, Georgia |
1999 - 2005 Wake Forest University School of Medicine Scholarship Selection Committee, Wake Forest University Medical School |
05/20/2000 - 05/22/2000 Co-Chair, Session on “Role of HDL in Atherosclerosis”, irst Conference on Atherosclerosis, Thrombosis and Vascular Biology 2000, Denver, CO |
2000 - 2004 Graduate Council Representative, Wake Forest University Senate, Wake Forest University Graduate School |
2000 Co-Chair, Session on “Lipoprotein Metabolism and Atherosclerosis in Transgenic and Knockout Animal Models”, 73rd Scientific Session, American Heart Association Meeting, New Orleans, Louisiana, 2000 |
2001 - 2005 Advisory Board, Jounral of Lipid Research |
2001 - 2012 Wake Forest University School of Medicine MD./PhD Applicant Interview Committee, Wake Forest University Medical School |
10/03/2002 - 10/06/2002 Chair, Session on Lipoprotein Metabolism, 11th Southeastern Lipid Conference, Callaway Gardens, GA |
09/18/2003 - 09/21/2003 Conference Co-Chair, 12th Southeastern Lipid Conference, Callaway Gardens, GA |
09/2003 External Advisor, Program Project, University of California - Davs |
2003 Panelist, Annual Forum on Graduate Education 2003, “Mentoring, What Every Graduate Student Wants to Know” sponsored by the Graduate School of Arts and Sciences, Wake Forest University, Wake Forest University Graduate School |
05/04/2004 - 05/08/2004 Judge, Irvine H. Page Young Investigator Award for the Council on Arteriosclerosis, Thrombosis and Vascular Biology, American Heart Association, at the Conference on Atherosclerosis, Thrombosis and Vascular Biology, San Francisco, California |
09/01/2004 - 09/01/2011 Kern Aspen Lipid Conference Board |
09/23/2004 - 09/25/2004 Conference Chair, 13th Southeastern Lipid Conference, Callaway Gardens, GA |
2004 Co-Chair, Session on “Novel Anti-Atherogenic Strategies”, 74th Scientific Session, American Heart Association Meeting, New Orleans, Louisiana, 2004 |
2004 - 2009 Member, Faculty Development and Career Committee, Wake Forest University Medical School |
2004 Co-Chair, Gordon Conference on Lipoprotein Metabolism |
2004 Department of Ob/Gyn Chair Search Committee, Wake Forest University Medical School |
2005 - 2019 Board Member, Kern Vail Lipid |
2005 Co-Chair, Session on “Cholesterol Trafficking and Homeostasis”, 75th Scientific Session, American Heart Association Meeting, Dallas, Texas, 2005 |
2006 Chair, Gordon Conference on Lipoprotein Metabolism |
2007 Translational Science Institute Symposium on Inflammation Planning Committee, Wake Forest University Medical School |
2007 - 2009 Member, National Heart Association, Arteriosclerosis, Thrombosis and Vascular Biology Annual Spring Meeting Program Committee |
2007 Abstract Grading Consultant, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Chicago IL 2007 |
2007 - 2009 Dean’s Advisory Committee, Wake Forest University Medical School |
2007 - 2009 Basic Science Representative for 2 terms, Faculty Executive Committee, Wake Forest University Medical School |
2008 - 2012 Charter Member, NIH, NHLBI, Atherosclerosis, Inflammation and Cardiovascular Science Study Section |
2008 Co-Chair, Plenary Session I. Lipid Metabolism and Mechanisms of Atherosclerosis Development, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Atlanta GA. 2008 |
2008 Abstract Grading Consultant, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Atlanta GA. 2008 |
2009 - 2011 Re-elected as the Basic Science Representative, Faculty Executive Committee, Wake Forest University Medical School |
2009 Abstract Grading Consultant, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Washington DC. 2009 |
2009 - 2011 Dean’s Advisory Committee, Wake Forest University Medical School |
2009 - 2011 Member, Faculty Development and Advancement Committee, Wake Forest University Medical School |
2009 Co-Chair, Concurrent Session on Lipid Metabolism. National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Washington DC. 2009 |
08/22/2010 Chair, Kern Aspen Lipid Meeting |
2010 - 2011 Faculty Executive Committee, Wake Forest University Medical School |
2011 Co-Chair, Session on Apoprotein Structure and Function. National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Chicago IL. 2011 |
2012 - Present Leadership Committee, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Council |
2012 - Present Nominating Committee, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Council |
2014 Member, Nominating Committee, Wake Forest University Medical School |
2015 - Present Board of Directors, Lipid Research, Inc (LRI) |
2015 - Present Standing Review Panel, American Heart Association Cardiovascular Genome-Phenome Study (CVGPS) |
2016 - 2022 Co-Chair, Chair, Atherosclerosis, Thrombosis and Vascular Biology Council of the American Heart Association |
2016 National Heart Lung and Blood Institute Board of Scientific Counselors, NHLBI Division of Intramural Research DIR Site Visit Review 2016 |
2016 Board of Scientific Counselors, National Heart Lung and Blood Institute Board of Scientific Counselors, NHLBI Division of Intramural Research DIR Site Visit Review 2016 |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
Local |
SR-BI and PCPE2 Modulate Lipid Traficking in Adipocytes, Endocrine Grand Rounds, Medical College of Wisconsin, Milwaukee, Wisconsin, 02/01/2018 |
Current Concepts in Cardiovascular Biology, Current Concepts in Cardiovascular Biology Course, Medical College of Wisconsin, Milwaukee, Wisconsin, 08/17/2021 |
National |
Presentation of: Cholesteryl esters do not remain intact in the circulation, 57th Annual Scientific Sessions of the American Heart Association, Miami, Florida, 11/11/1984 - Present |
Presentation of: Regulation of apolipoprotein AI mRNA levels by dietary fat and cholesterol, 58th Annual Scientific Sessions of the American Heart Association, Washington, DC, 11/12/1985 |
Presentation of: Transcription of the monkey apoE gene, 58th Annual Scientific Sessions of the American Heart Association, Washington, DC, 11/12/1985 |
Presentation of: Effects of dietary fat and cholesterol on apoprotein A-I mRNA abundance in nonhuman primates, Research Institute, Palo Alto Medical Foundation, Palo Alto, CA, 09/05/1986 |
Presentation of: Cholesteryl esters do not remain intact in the circulation, University of Washington, Department of Medicine, Division of Metabolism, Seattle, Washington, 09/08/1986 |
Presentation of: Effects of dietary fat and cholesterol on apoprotein A-I mRNA abundance in nonhuman primates, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 11/03/1986 |
Presentation of: Peripheral apolipoprotein AI mRNA abundance in the nonhuman primate, 59th Annual Scientific Sessions of the American Heart Association, Dallas, Texas, 11/19/1986 |
Presentation of: Effects of dietary fat and cholesterol on the expression of genes encoding apoA-I, A-II, B and E in the liver and small intestine of nonhuman primates, NIH Conference on the Effects of Diet Composition on Apolipoprotein Metabolism, Phoenix, Arizona, 02/19/1987 |
Poster presentation of: Liver low density lipoprotein receptor mRNA levels in cholesterol-fed nonhuman primates, 60th Annual Scientific Sessions of the American Heart Association, Anaheim, California, 11/17/1987 |
Poster presentation of: Regulation of apolipoprotein gene expression, Gordon Research Conference, Lipid Metabolism, Meriden, NH, 06/21/1989 |
Presentation of: Regulation of apolipoprotein A-I gene expression, Louisiana State University Medical Center Department of Physiology, New Orleans, Louisiana, 10/10/1989 |
Presentation of " Transcriptional regulation of apolipoprotein A-I gene in nonhuman primates with low and high susceptibilities to diet induced atherosclerosis", Warner-Lambert Parke-Davis, Ann Arbor, MI, 11/02/1989 |
Poster presentation of: Transcriptional regulation of apolipoprotein A-I gene in nonhuman primates with low and high susceptibilities to diet induced atherosclerosis, 62nd Annual Scientific Sessions of the American Heart Association, New Orleans, Louisiana, 11/18/1989 |
Presentation of: Nutritional regulation of apolipoprotein and low density lipoprotein gene expression, Pfizer Central Research, Department of Metabolic Diseases, Groton, Connecticut, 02/12/1990 |
Presentation of: Regulation of apolipoprotein gene expression in nonhuman primates fed dietary fat and cholesterol, Division of Cardiovascular Research Schering-Plough, Bloomfield, N.J, 12/16/1990 - 12/16/1900 |
Presentation of: Genetic regulation of ApoA-I, Columbia University, Department of Medicine, New York, New York, 12/17/1990 |
Presentation of: Transcriptional Regulation of Apolipoprotein A-I, University Southern California, Department of Pharmacology and Toxicology, Los Angeles, CA, 06/10/1991 |
Presentation of: Transcriptional regulation of the apolipoprotein A-I gene, 64th Annual Scientific Sessions of the American Heart Association, Anaheim, California, 11/11/1991 |
Poster presentation of: Species-specific regulation of the apoA-I gene, University of California at San Diego Asilomar Conference, Molecular and Cellular Biology of the Cardiac Myocyte, Pacific Grove, California, 11/18/1991 |
Poster presentation of: Structure:function relationships of ApoA-I, hird International Conference on HDL and Atherosclerosis, San Antonio, TX, 03/05/1992 |
Poster presentation of: Structure:function relationships of ApoA-I, Gordon Research Conference, Lipid Metabolism, Meriden, N.H, 06/18/1992 |
Presentation of: Transcriptional Regulation of Apolipoprotein A-I: Cis-Element Crosstalk, Oncogene Sciences, Inc., Long Island, New York, 07/08/1992 |
Presentation of: LCAT activation and amphipathic -helical domains of apoA-I, Department of Medicine/Cardiology at the University of California at Los Angeles, Los Angeles, CA, 08/03/1992 |
Presentation of: Transcriptional Regulation of the ApoA-I Gene: Cross Talk between Distinct Regions of the Promoter, Division of Liver Biology at Monsanto/Searle Corporate Research, St. Louis, Missouri,, 09/15/1992 |
Presentation of: Regulation of ApoA-I Expression: Heredity vs. Diet, Division of Cardiovascular Research at Washington University School of Medicine, St Louis, Missouri, 09/16/1992 |
Presentation of: Structure:function Relationships of ApoA-I, Lipid Investigator Research Conference at Merck, Human Health Division, Rahway, New Jersey, 10/24/1992 |
Presentation of: ApoA-I Regulations: Structural Determinants and Atherogenesis, Cardiovascular Central Nervous System Research Section of American Cyanamid Company, Lederle Laboratories, Pearl River, New York, 01/20/1993 |
Presentation of: ApoA-I Regulation:Structural Determinants and Atherogenesis, Department of Biochemistry, East Carolina School of Medicine, Greenville, NC, 02/15/1993 |
Presentation of: Regulation of Apolipoprotein Gene Expression in Nonhuman Primates and Model Systems, The University of North Carolina at Greensboro, School of Human Environmental Sciences, The University of North Carolina at Greensboro, School of Human Environmental Sciences Department of Food, Nutrition and Food Service Management, 03/15/1993 |
Presentation of: Site-directed Mutagenesis in Structure:Function Studies, Southeastern Lipoprotein Conference, Callaway Gardens, Georgia, 04/16/1993 |
Presentation of: Apolipoprotein A-I Domains Involved in Lecithin:Cholesterol Acyltransferase Activation. Structure:Function Relationships., Department of Biochemistry, University of Illinois, Urbana, Illinois, 09/24/1993 |
Presentation of: Species-Specific Expression of the ApoA-I Gene is Regulated by Point Mutations in the Promoter Region, American Heart Association Meetings, Atlanta, Georgia, 11/08/1993 |
Poster presentation of: LCAT Activation and the Interaction Between Adjacent alpha-helical Domains in ApoA-I, Gordon Research Conference on Lipid Metabolism, Meriden, New Hampshire, 06/19/1994 - 06/24/1994 |
Presentation of: Apolipoprotein A-I Domains Involved in Lecithin:cholesterol Acyltransferase Activation. Structure:Function Relationships, Division of Gerontology/Geriatric Medicine, Dept. of Medicine, University of Alabama School of Medicine, Birmingham, AL, 07/06/1994 |
Poster Presentation of: The Role of Inter-Molecular Helical Interaction in Apolipoprotein A-I Activation of Lecithin:Cholesterol Acyltransferase, American Heart Association 67th Scientific Sessions, Dallas, TX, 11/14/1994 |
Poster Presentation of: Alternation in Apo A-I 22-mer Repeat Order Reduces its Ability to Activate LCAT, Gordon Research Conference on Lipid Metabolism, Meriden, New Hampshire, 06/19/1996 |
Poster Presentation of: Alteration in Apo A-I 22-mer Repeat Order Reduces its Ability to Activate LCAT, American Heart Association 69th Scientific Sessions, New Orleans, LA, 11/10/1996 - 11/13/1996 |
Presentation of: Alteration in ApoA-I 22-mer Repeat Order Reduces its Ability to Activate LCAT, National Heart, Lung, and Blood Institute, DHVD, Bethesda, MD, 12/04/1996 |
Presentation of: Apo AI ∆6 (∆143-164) Transgenic Mice Acquire Severe Hypoalphalipoproteinemia in the Absence of Endogenous Mouse Apo A-I, Southeast Lipid Conference, Lake Lanier Islands Hilton Resort, Georgia, 09/05/1997 |
Poster Presentation of: Transgenic Model of Severe Hypoalphalipoproteinemia Resulting from the Deletion of a Single 22-mer Repeat within Apo A-I, American Heart Association 70th Scientific Sessions, Orlando, FL, 11/11/1997 |
Presentation of: Unique Features of the 143-164 Residue Domain of Apo A-I. Studies of LCAT Activation in vitro and in vivo, Workshop on HDL/Apo A-I Structure:Function, 7th Annual Southeast Lipid Conference, Lake Lanier Hilton Resort, Georgia, 09/11/1998 |
Presentation of: Apolipoprotein A-I Mutation Blocks Pre-HDL Particle Formation and Maturation in Transgenic Mice, American Heart Association 71st Scientific Sessions, Dallas, Texas, 11/11/1998 |
Visiting Professorship, University of Alabama at Birmingham, 04/26/1999 - 04/30/1999 |
Presentation of: Unique Features of the 143-164 Residue Domain of Apo A-I: Studies of LCAT Activation in vitro and in vivo, Gladstone Institute of Cardiovascular Disease, San Francisco, CA, 05/17/1999 |
Presentation of: “Apo A-I Mutants and LCAT Activity”, 8th Southeastern Lipid Conference, Lake Lanier, Georgia, 09/10/1999 |
Presentation of: “Apo A-I Mutation Reduces LCAT Catalyzed Plasma Cholesterol Esterification in the Presence of Wild-Type Apo A-I”, American Heart Association 72nd Scientific Sessions, Atlanta, Georgia, 11/07/1999 |
Presentation of "The Effects of Mutant Forms of Apo A-I on HDL Concentration and Risk for Atherosclerosis", Warner-Lambert Parke-Davis, Ann Arbor, MI, 02/10/2000 - 02/11/2000 |
Keynote address of “The Role of Mutant forms of Apo A-I on HDL Metabolism and Atherosclerosis”, First Conference on Atherosclerosis, Thrombosis and Vascular Biology 2000, Denver CO, 05/21/2000 |
Presentation of: “Effect of Mutant forms of Apo A-I on HDL Metabolism and Atherosclerosis, The Gordon Conference on Lipid Metabolism, Meriden NH, 07/24/2000 - 07/30/2000 |
Presentation of: “Intravascular Metabolism of HDL and Mutant forms of Apo A-I“, Ninth Annual Southeastern Lipid Research Conference, Lake Lanier Islands Hilton Resort, Georgia, 09/08/2000 |
Presentation of “The Effect of Mutant Forms of Apo A-I on HDL Concentration and Risk for Atherosclerosis”, Appalachian State University, Boone, NC, 09/20/2000 |
Poster presentation of: “Intracellular Quality Control in the Apo A-I Secretory Pathway: Accumulation of Phospholipid and ∆6 apo A-I Inclusions, American Heart Association 73rd Scientific Sessions, New Orleans, Louisiana, 11/13/2000 |
Presentation of: “Apo A-I Polymorphisms: Impact on HDL Concentration”: Assessing HDL as a Risk Factor in Coronary Heart Disease, A Working Group Meeting Sponsored by Merck HHD, Scottsdale, Arizona, 01/12/2001 - 01/13/2001 |
Presentation of: “Human Apo A-I Polymorphisms and HDL Metabolism: Association with LCAT Activation by Apo A-I”, Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio, 04/05/2001 |
Presentation of: “Human Apo A-I Polymorphisms and HDL Metabolism”, Department of Pathology, University of Chicago, Chicago, Illinois, 04/30/2001 |
Presentation of: “Human Apo A-I Polymorphisms and their Effects on HDL Metabolism”, Department of Nutritional Sciences, University of Kentucky, Lexington, Kentucky, 05/25/2001 |
Presentation of “Human Apo A-I Polymorphisms and their Effects on HDL Metabolism, Pfizer Research, Ann Arbor, MI, 08/29/2001 - 08/30/2001 |
Presentation of: “Effects of ApoA-I Mutations on HDL Concentrations : Insights From FRET Studies”, Department of Pathology, University of Chicago, Chicago, Illinois, 07/17/2002 |
Presentation of “Studies in Mice Lacking Both LDL Receptors and ApoA-I”, 11th South Eastern Lipoprotein Research Conference, Callaway Gardens, Georgia, 10/04/2002 |
Presentation of “HDL Apo A-I Mutations and their Effects on Cholesterol Homeostasis”, 4th Annual International Conference on HDL Cholesterol; Metabolic Pathways and Drug Development, Boston, MA, 03/03/2003 - 03/05/2003 |
Presentation of “Inhibition of Reverse Cholesterol Transport in LDLr-/-, ApoA-I-/- Mice Leads to Inflammation and Atherosclerosis, Children’s Hospital of Oakland Research Institute, Oakland, CA, 05/05/2004 |
Presentation of “Inhibition of Reverse Cholesterol Transport in LDLr-/-, ApoA-I-/- Mice Leads to Inflammation and Atherosclerosis”, 2004 Gordon Conference on Lipoprotein Metabolism, Meriden, NH, 06/14/2004 |
Presentation of “Structural studies of lipid-bound apoA-I using chemical cross-linking and mass spectrometry”, Vanderbilt University, Nashville, TN, 09/14/2004 |
Presentation of “Inhibition of reverse cholesterol transport in LDLr-/-, ApoA-I-/- mice leads to inflammation and atherosclerosis”, 2005 Deuel Conference on Lipids, Dana Point, CA, 03/01/2005 - 03/04/2005 |
Presentation of “Linking the tertiary structure of apoA-I to its anti-atherogenic role in HDL metabolism”, 2005 Aspen Kern Lipid Conference, Aspen, CO, 08/20/2005 - 08/23/2005 |
Presentation of “3-dimensional information on the lipid-bound conformation of apoA-I”, 005 David L. Williams Memorial Symposium on “Molecular Mechanisms Regarding Cholesterol Metabolism in Atherosclerosis”, Stony Brook, NY, 10/28/2005 |
Presentation of “The role of HDL ApoA-I in Inflammation and Cholesterol Homeostasis”, 2006 Winter Gordon Conference on Oxygen Radicals, Ventura Beach, CA, 02/07/2006 |
Presentation of “Linking the tertiary structure of apoA-I to its anti-atherogenic role in HDL metabolism”, Boston University, Department of Pharmacology and Biophysics, Boston, MA, 05/08/2006 - 05/09/2006 |
Presentation of “Three dimensional models of high density lipoprotein apoA-I: Implications for its assembly and function”, Department of Medicine at the University of Washington, Seattle, WA, 12/12/2007 - 12/14/2007 |
Presentation of “Collaborations Present and Future: Mouse Models of Atherosclerosis”, First Annual Hypertension and Vascular Research Center Global Retreat, Wake Forest University Health Sciences, 01/10/2008 |
Presentation of “Three dimensional models of high density lipoprotein apoA-I: Implications for its assembly and function", Robert M. Berne Cardiovascular Research Center at the University of Virginia, Charlottesville, VA, 02/06/2008 |
Presentation of “Three dimensional models of high density lipoprotein apoA-I: Implications for its assembly, maturation and function”, 2008 Gordon Conference on Lipoprotein Metabolism, Waterville, NH, 06/22/2008 |
Presentation of “ApoA-I Structure and Function: Regulation of Cholesterol Homeostasis and Inflammation”, NIH NHLBI Conference on HDL Structure and Function, Washington, DC, 04/27/2009 |
Presentation of “Three dimensional models of high density lipoprotein apoA-I: Implications for its assembly and lipidation”, Spring HDL ApoA-I Structure Workshop, Washington, DC, 05/02/2009 |
Presentation of “ApoA-I Structure and Function: Regulation of Cholesterol Homeostasis and Inflammation”, Medical University of South Carolina, Charleston, SC, 05/14/2009 |
Presentation of “ApoA-I Structure and Function: Regulation of Cholesterol Homeostasis and Inflammation”, Columbia University, New York, NY, 05/27/2009 |
Presentation of “ApoA-I Structure and Function: Regulation of Cholesterol Homeostasis and Inflammation”, SUNY Downstate Medical Center, Brooklyn, NY, 05/28/2009 |
Presentation of “HDL, ApoA-I Its Role in Autoimmunity and Cholesterol Homeostasis”, University of Kentucky, Lexington, KY, 12/17/2009 |
Presentation of “Autoimmunity and Cholesterol Homeostasis”, Gordon Research Conferences on Lipoprotein Metabolism, Waterville Valley, NH, 06/22/2010 |
Presentation of “HDL, ApoA-I and its role in Regulating Autoimmunity”, Kern Aspen Lipid Conference, Aspen, Colorado, 08/22/2010 |
Presentation of “HDL ApoA-I What Makes It Act As The “Good Cholesterol?”, Rutgers University, New Brunswick, New Jersey, 09/27/2010 |
Presentation of “Why is HDL ApoA-I Anti-Atherogenic and Anti-Inflammatory? It’s All About the Cholesterol!”, 75th New York Lipid Club Meeting, Rockefeller University, New York, New York, 09/28/2010 |
Presentation of “HDL ApoA-I; What Makes It Protective or the “Good Cholesterol?”, Southeast Lipid Research Conference, Pine Mountain, Georgia, 10/09/2010 |
Presentation of “Biogenesis of Nascent HDL”, 10th Arteriosclerosis Thrombosis and Vascular Biology Meeting, Chicago, IL, 04/28/2011 |
Presentation of “HDL ApoA-I and Its Role in Autoimmunity and Atherosclerosis”, HDL ApoA-I Structure Workshop, Chicago, IL, 05/01/2011 |
Presentation of “HDL ApoA-I and Autoimmunity”, Gordon Conference on Atherosclerosis, Newport, Rhode Island, 06/22/2011 |
Presentation of “High Density Lipoproteins, Autoimmunity and Atherosclerosis”, La Jolla Institute for Allergy and Inflammation, La Jolla, CA, 02/22/2012 |
Presentation of “HDL ApoA-I and Its Role in Autoimmunity and Atherosclerosis”, Keystone Symposium on the Molecular Basis of Inflammation and Atherosclerosis, Big Sky, MT, 03/26/2012 |
Poster Presentation of: “3-Dimensional Conformation of HDL ApoA-I Generated via ABCA1“, American Heart Association; Atherosclerosis, Thrombosis and Vascular Biology Meeting (ATVB), Chicago, IL, 04/20/2012 |
Presentation of “Cholesterol Efflux, Microdomains and the Role of Nascent HDL Biogenesis in Chronic Inflammation and Atherosclerosis”, HDLApoA-I Structure Workshop following ATVB Conference, Chicago, IL, 04/21/2012 |
Presentations of “Cholesterol Efflux, Microdomains and the Role of Nascent HDL Biogenesis” and Role of ApoA-I in Chronic Inflammation and Atherosclerosis”, Department of Medicine at the University of Washington, Seattle, Seattle, WA, 05/23/2012 - 05/24/2012 |
Presentation of “Cholesterol Efflux, Microdomains and the Role of Nascent HDL Biogenesis in Atherosclerosis”, Gordon Research Conference on Lipoprotein Metabolism, Waterville Valley, NH, 06/20/2012 |
Presentation of: “HDL, Autoimmunity and Atherosclerosis”, Southeast Lipid Research Conference, Pine Mountain, Georgia, 09/26/2012 - 09/29/2012 |
Presentation of: HDL, Atherosclerosis and Autoimmunity”, American Heart Association Meetings, Los Angeles, CA, 11/02/2012 - 11/07/2012 |
Poster Presentation of: “Lipid Acquisition and a Novel Role for PCPE2“, American Heart Association; Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Conference, Orlando, FL, 04/30/2013 - 05/04/2013 |
Presentation of “PCPE2- A Novel Determinant in HDL Biogenesis and Metabolism”, HDL ApoA-I Structure Workshop following ATVB Conference, Orlando, FL, 05/03/2013 |
Presentation of “PCPE2- A Novel Determinant in HDL Biogenesis and Metabolism”, LSU Pennington Biomedical Research Center, Baton Rouge, LA, 09/09/2013 |
Presentation of “PCPE2, Atherosclerosis and HDL Function”, The Medical College of Wisconsin, Milwaukee, WI, 02/03/2014 |
Presentation of “PCPE2, SR-BI and HDL Function”, Department of Cellular Biology and Anatomy LSU Health Sciences Shreveport, Shreveport, LA, 10/05/2014 - 10/07/2014 |
Keynote Speaker, Nutritional Graduate Student Association Symposium, Texas A&M University, 03/09/2015 |
Presentation of “PCPE2, SR-BI and HDL Function”, New York University Langone Medical Center Retreat, Putnam Valley, NY, 06/20/2015 |
Presentation of “PCPE2, SR-BI and HDL Function”, Gordon Research Conference on Atherosclerosis, Sunday River, ME, 06/22/2015 |
Presentation of “PCPE2, SR-BI and Reverse Cholesterol Transport”, Texas A&M, Department of Nutrition Science, College Station, TX, 10/11/2015 |
Presentation of “Procollagen C-endopeptidase Enhancer Protein 2 (PCPE2) Deficiency Profoundly Affects Adipose Distribution in Mice and Humans Linking HDL Metabolism to Adipocyte Biology”, 15th annual ATVB Conference, Nashville, TN, 05/06/2016 |
International |
Presentation of: Gene Regulation of Apolipoprotein AI: Identification of Species-Specific Cis-Acting Elements, Department of Medicine and the Robarts Research Institute, University of Western Ontario, London, Canada, 12/10/1992 |
Presentation of: Gene Regulation of Apolipoprotein AI: Identification of Species Specific Cis-Acting Elements, University of Toronto, St. Michael's Hospital, Lipid Research Group, Toronto, Canada, 12/11/1992 |
Presentation of: LCAT Activation and the Interaction Between Adjacent-helical Domains in Apolipoprotein A-I, Department of Biochemistry, The University of Queensland, Brisbane, Australia, 10/27/1994 |
Presentation of: Apo A-I Cis-Acting Elements Responsible for High Level Expression, Allelix Biopharmaceuticals, Inc, Mississauga, Ontario, Canada, 10/22/1996 |
Presentation of: Alteration in Apolipoprotein A-I 22-mer Repeat Order Results in a Decrease in Lecithin:Cholesterol Acyltransferase Reactivity, Lipid and Lipoprotein Research Group, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada, 04/04/1997 |
Presentation of “Alternate conformations of lipid-bound apoA-I delineated by cross-link analysis and mass spectrometry”, 2004 HDL Workshop, Heraklion, Crete, Greece, 09/03/2004 |
Presentation of “Three Dimensional Information on the Lipid-Bound Conformation of ApoA-I”, 2006 XIV International Symposium on Atherosclerosis-Satellite Symposium: HDL From Basic Science to Therapeutic Applications, Parma, Italy, 06/23/2006 - 06/24/2006 |
Presentation of “Conformational adaptation of apolipoprotein A-I to discretely sized phospholipid complexes”, The International Atherosclerosis Society Workshop on HDL Structure, Protective Functions and Therapeutic Applications, Santorini, Greece, 10/09/2007 - 10/12/2007 |
Presentation of “Regulatory T Cells, Autoimmunity and Cholesterol Homeostasis”, 6th International Atherosclerosis Society Sponsored Workshop on HDL, Whistler, BC Canada, 05/19/2010 |
Presentation of “PCPE2- A Novel Determinant in HDL Function”, HDL ApoA-I Structure Workshop following ATVB Conference, Toronto, Canada, 05/03/2014 |
COMMITTEE SERVICE: |
Medical College of Wisconsin |
2015 Chair, Mentoring Committee for Srividya Kidambi. MD, Medical College of Wisconsin |
2015 Chair, Mentoring Committee for Michael Yeboah, MD Ph.D, Medical College of Wisconsin |
2016 Associate Program Director, Cardiovascular Center T32 “Training in Signature Transdisciplinary Cardiovascular Sciences”, Medical College of Wisconsin |
2016 Cardiovascular Center Core Equipment Advisory Committee, Medical College of Wisconsin |
EXTRAMURAL TEACHING: |
Medical Student Education |
1987 - 1988 Wake Forest University School of Medicine, Winston-Salem, NC, Instructor, Department of Comparative Medicine |
1991 - 1998 Wake Forest University School of Medicine, Small group discussion leader for 1) Lipoprotein/ Atherosclerosis Section and 2) Oncogenes/Cancer for the General Biochemistry Unit I |
Resident and Fellow Education |
1993 - 1996 Wake Forest University School of Medicine, Served on an NIH Gerontology Fellowship Training Grant Oversight Committee. This training grant was directed by Dr. Walter Ettinger, Professor of Medicine. Our committee met quarterly to evaluate the research progress of each of the 7 fellows supported by the grant. |
Graduate Student Education |
1987 - 2014 Wake Forest University School of Medicine, Each year I have directed the research of one or two graduate students who have rotated through my laboratory. |
1988 - 2014 Wake Forest University School of Medicine, 1-Semester Graduate Level Course in Disturbances in Lipoprotein Metabolism-COMD 709. My contribution to this group taught course is 2-3 1-hour lectures. |
1988 - 2014 Wake Forest University School of Medicine, 2-Semester Graduate Level Course in Molecular Biology - Molecular Genetics 731 and 732. My contribution to this group taught course 7-8 1.5 hour lectures. |
1988 - 2014 Wake Forest University School of Medicine, 1 Semester Graduate Level Course in Pathobiology of Atherosclerosis-PATH 417. My contribution to this group taught course is 2-3 1 hr lectures |
EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Medical Students |
Wake Forest University School of Medicine, Department of Biochemistry, 1979 - 1982 Tutored medical students in General Biochemistry and lead group discussions on specific areas such as Acid:Base Chemistry and Enzymology. Graduate Teaching Assistant in Biochemistry. |
Shari Orlieck,M.D. - Pediatrics, Wake Forest University School of Medicine, 1988 - 1990 Mentor/Advisor |
Wake Forest University School of Medicine, 1999 - 2001 Faculty Tutor, Phase IIC and IB of the Basic and Clinical Science Problems Course WFUBMC |
Diana Rubin (MSIV), Medical Student Mentorship Program, 2000 - 2002 Medical Student Mentorship Program |
Candice Brown, Ph.D - Internal Medicine, Wake Forest University School of Medicine, 2011 Mentor/Advisor |
Susan Brock, Salem College in Winston-Salem, NC, Mentor for an Experimental Mentoring Program |
Graduate Students |
1990, Fall of 1990, I planned and organized a Tutorial Program from the graduate students at WFUBMC. Dr. Lawrence Chan, from Baylor University, tutored our students on the “Molecular Genetics of Apolipoproteins”. |
2003, Participated as one of 5 panelist in a 2003 Graduate Forum on Mentoring Graduate Students. Panelist represented different areas of career s after obtaining a Ph.D. in Biomedical Studies. |
Postdoctoral Students |
Vivek K. Varma, M.D, 1988 - 1990 Mentor/Advisor |
Melanie T. Paff, Ph.D., Wake Forest University School of Medicine, 1993 - 1996 Mentor/Advisor |
Hui-hua Li, M.D., Ph.D., Wake Forest University School of Medicine, 1998 - 2002 Mentor/Advisor |
Shaila Bhat, Ph.D., 2000 - 2010 Mentor/Advisor |
Mannish Bharadwaj, Ph.D., Wake Forest University School of Medicine, 2003 - 2007 Mentor/Advisor |
Lijun Tang, MD. Ph.D., 2005 - 2006 Mentor/Advisor |
Kristina Brzoza-Lewis, Ph.D., Wake Forest University School of Medicine, 2010 - 2014 Mentor/Advisor |
Chris Blesso, Ph.D., Wake Forest University School of Medicine, 2012 - 2014 Mentor/Advisor |
Clinical/Research Fellows |
1992 - 1993 Research, supported by an American Heart Association. Mr. Lee took a 1 yr leave from medical school to do research in my laboratory. |
John Owen, Ph.D., Wake Forest University School of Medicine, 2005 - 2011 Research Associate Directed |
ACTIVE GRANTS: |
07/16/2012 - 06/30/2016 1R01HL112270-01A1
National Institutes of Health/NHLBI
Multiple Principle Investigator (Pritchard, KA (contact); Sorci-Thomas, Mary G)
Project Entitled: “Biophysics of HDL Dysfunction”
This project will investigate the mechanism by which chronic states of oxidative stress and inflammation impair HDL function.
|
06/01/2013 - 04/30/2017 1R01HL112276-01A1
National Institutes of Health/NHLBI
Multiple Principle Investigator (Hedrick, Catherine (contact); Sorci-Thomas, Mary G)
Project Entitled: “T Regulatory Lymphocytes, HDL Function, and Atherosclerosis”
This project will examine T regulatory lymphocytes (Treg) and the role of high-density lipoprotein (HDL) transport of sphingosine-1- phosphate (S1P) on their modulation during the process of atherogenesis.
|
07/12/2013 - 06/30/2018 1RO1 HL118206-01
National Institutes of Health/NHLBI
Principle Investigator (Randolph, G)
Participating Investigator (Sorci-Thomas and Thomas)
Project Entitled: “VEGF-C/VEGFR3 and Lymphatic Transport of Cholesterol from Atherosclerotic Plaque”
|
PENDING GRANTS: |
1RO1HL119847-01
National Institutes of Health/NHLBI
Principle Investigator (Sorci-Thomas)
Project Entitled: “HDL ApoA-I Processing and Biogenesis During ABCA1 Mediated Cholesterol Efflux”
This project will investigate and define the novel role for Procollagen C Proteinase Enhancer 2 (PCPE2) in the formation and function of HDL as it relates to the progression of atherosclerosis.
|
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Sorci-Thomas M, Prack MM, Dashti N, Johnson F, Rudel LL, Williams DL. Apolipoprotein (apo) A-I production and mRNA abundance explain plasma apoA-I and high density lipoprotein differences between two nonhuman primate species with high and low susceptibilities to diet-induced hypercholesterolemia. J Biol Chem. 1988 Apr 15;263(11):5183-9. |
2. Sorci-Thomas M, Prack MM, Dashti N, Johnson F, Rudel LL, Williams DL. Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: relationship to plasma concentration of high density lipoproteins. J Lipid Res. 1989 Sep;30(9):1397-403. |
3. Sorci-Thomas M, Wilson MD, Johnson FL, Williams DL, Rudel LL. Studies on the expression of genes encoding apolipoproteins B100 and B48 and the low density lipoprotein receptor in nonhuman primates. Comparison of dietary fat and cholesterol. J Biol Chem. 1989 May 25;264(15):9039-45. |
4. Sorci-Thomas M, Babiak J, Rudel LL. Lecithin-cholesterol acyltransferase (LCAT) catalyzes transacylation of intact cholesteryl esters. Evidence for the partial reversal of the forward LCAT reaction. J Biol Chem. 1990 Feb 15;265(5):2665-70. |
5. Sorci-Thomas M, Kearns MW. Transcriptional regulation of the apolipoprotein A-I gene. Species-specific expression correlates with rates of gene transcription. J Biol Chem. 1991 Sep 25;266(27):18045-50. |
6. Sorci-Thomas M, Hendricks CL, Kearns MW. HepG2 cell LDL receptor activity and the accumulation of apolipoprotein B and E in response to docosahexaenoic acid and cholesterol. J Lipid Res. 1992 Aug;33(8):1147-56. |
7. Varma VK, Smith TK, Sorci-Thomas M, Ettinger WH Jr. Dexamethasone increases apolipoprotein A-I concentrations in medium and apolipoprotein A-I mRNA abundance from Hep G2 cells. Metabolism. 1992 Oct;41(10):1075-80. |
8. Colvin PL Jr, Wagner JD, Heuser MD, Sorci-Thomas MG. Oral contraceptives decrease hepatic cholesterol independent of the LDL receptor in nonhuman primates. Arterioscler Thromb. 1993 Nov;13(11):1645-9. |
9. Sorci-Thomas M, Kearns MW, Lee JP. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. Structure:function relationships. J Biol Chem. 1993 Oct 05;268(28):21403-9. |
10. Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK, Verdery RB. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb. 1994 Jan;14(1):8-13. |
11. Shanker G, Sorci-Thomas M, Register TC, Adams MR. The inducible expression of THP-1 cell interleukin-1 mRNA: effects of estrogen on differential response to phorbol ester and lipopolysaccharide. Lymphokine Cytokine Res. 1994 Feb;13(1):1-7. |
12. Keiger CJ, O'Steen WK, Brewer G, Sorci-Thomas M, Zehnder TJ, Rose JC. Corticotropin releasing factor mRNA and peptide levels are differentially regulated in the developing ovine brain. Brain Res Mol Brain Res. 1994 Nov;27(1):103-10. |
13. Shanker G, Sorci-Thomas M, Adams MR. Estrogen modulates the expression of tumor necrosis factor alpha mRNA in phorbol ester-stimulated human monocytic THP-1 cells. Lymphokine Cytokine Res. 1994 Dec;13(6):377-82. |
14. Sorci-Thomas M, Kearns MW. Species-specific polymorphism in the promoter of the apolipoprotein A-I gene: restoration of human transcriptional efficiency by substitution at positions -189, -144 and -48 bp. Biochim Biophys Acta. 1995 Jun 06;1256(3):387-95. |
15. Keiger CJ, O'Steen WK, Brewer G, Sorci-Thomas M, Zehnder TJ, Rose JC. Cortisol up-regulates corticotropin releasing factor gene expression in the fetal ovine brainstem at 0.70 gestation. Brain Res Mol Brain Res. 1995 Aug;32(1):75-81. |
16. Shanker G, Sorci-Thomas M, Adams MR. Estrogen modulates the inducible expression of platelet-derived growth factor mRNA by monocyte/macrophages. Life Sci. 1995;56(7):499-507. |
17. Miller KR, Wang J, Sorci-Thomas M, Anderson RA, Parks JS. Glycosylation structure and enzyme activity of lecithin:cholesterol acyltransferase from human plasma, HepG2 cells, and baculoviral and Chinese hamster ovary cell expression systems. J Lipid Res. 1996 Mar;37(3):551-61. |
18. Sorci-Thomas MG, Parks JS, Kearns MW, Pate GN, Zhang C, Thomas MJ. High level secretion of wild-type and mutant forms of human proapoA-I using baculovirus-mediated Sf-9 cell expression. J Lipid Res. 1996 Mar;37(3):673-83. |
19. Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW. Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity. J Biol Chem. 1997 Mar 14;272(11):7278-84. |
20. Colvin PL Jr, Wagner JD, Adams MR, Sorci-Thomas MG. Sex steroids increase cholesterol 7alpha-hydroxylase mRNA in nonhuman primates. Metabolism. 1998 Apr;47(4):391-5. |
21. Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW, Landrum M. The hydrophobic face orientation of apolipoprotein A-I amphipathic helix domain 143-164 regulates lecithin:cholesterol acyltransferase activation. J Biol Chem. 1998 May 08;273(19):11776-82. |
22. Sorci-Thomas MG, Thomas M, Curtiss L, Landrum M. Single repeat deletion in ApoA-I blocks cholesterol esterification and results in rapid catabolism of delta6 and wild-type ApoA-I in transgenic mice. J Biol Chem. 2000 Apr 21;275(16):12156-63. |
23. Li H, Lyles DS, Thomas MJ, Pan W, Sorci-Thomas MG. Structural determination of lipid-bound ApoA-I using fluorescence resonance energy transfer. J Biol Chem. 2000 Nov 24;275(47):37048-54. |
24. Thomas MJ, Chen Q, Zabalawi M, Anderson R, Wilson M, Weinberg R, Sorci-Thomas MG, Rudel LL. Is the oxidation of high-density lipoprotein lipids different than the oxidation of low-density lipoprotein lipids? Biochemistry. 2001 Feb 13;40(6):1719-24. |
25. Thomas MJ, Chen Q, Sorci-Thomas MG, Rudel LL. Isoprostane levels in lipids extracted from atherosclerotic arteries of nonhuman primates. Free Radic Biol Med. 2001 Jun 15;30(12):1337-46. |
26. Li HH, Thomas MJ, Pan W, Alexander E, Samuel M, Sorci-Thomas MG. Preparation and incorporation of probe-labeled apoA-I for fluorescence resonance energy transfer studies of rHDL. J Lipid Res. 2001 Dec;42(12):2084-91. |
27. Reschly EJ, Sorci-Thomas MG, Davidson WS, Meredith SC, Reardon CA, Getz GS. Apolipoprotein A-I alpha -helices 7 and 8 modulate high density lipoprotein subclass distribution. J Biol Chem. 2002 Mar 22;277(12):9645-54. |
28. Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med. 2002 Apr;12(3):121-8. |
29. Li HH, Lyles DS, Pan W, Alexander E, Thomas MJ, Sorci-Thomas MG. ApoA-I structure on discs and spheres. Variable helix registry and conformational states. J Biol Chem. 2002 Oct 18;277(42):39093-101. |
30. Schwenke DC, Rudel LL, Sorci-Thomas MG, Thomas MJ. Alpha-tocopherol protects against diet induced atherosclerosis in New Zealand white rabbits. J Lipid Res. 2002 Nov;43(11):1927-38. |
31. Zabalawi M, Bhat S, Loughlin T, Thomas MJ, Alexander E, Cline M, Bullock B, Willingham M, Sorci-Thomas MG. Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol. Am J Pathol. 2003 Sep;163(3):1201-13. PMCID: PMC1868257 |
32. Bhat S, Zabalawi M, Willingham MC, Shelness GS, Thomas MJ, Sorci-Thomas MG. Quality control in the apoA-I secretory pathway: deletion of apoA-I helix 6 leads to the formation of cytosolic phospholipid inclusions. J Lipid Res. 2004 Jul;45(7):1207-20. |
33. Alexander ET, Bhat S, Thomas MJ, Weinberg RB, Cook VR, Bharadwaj MS, Sorci-Thomas M. Apolipoprotein A-I helix 6 negatively charged residues attenuate lecithin-cholesterol acyltransferase (LCAT) reactivity. Biochemistry. 2005 Apr 12;44(14):5409-19. |
34. Bhat S, Sorci-Thomas MG, Alexander ET, Samuel MP, Thomas MJ. Intermolecular contact between globular N-terminal fold and C-terminal domain of ApoA-I stabilizes its lipid-bound conformation: studies employing chemical cross-linking and mass spectrometry. J Biol Chem. 2005 Sep 23;280(38):33015-25. |
35. Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, Signorino P, Densmore JC, Kaul S, Oldham KT, Pritchard KA Jr. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res. 2005 Nov 25;97(11):1190-7. PMCID: PMC1480357 |
36. Thomas MJ, Bhat S, Sorci-Thomas MG. The use of chemical cross-linking and mass spectrometry to elucidate the tertiary conformation of lipid-bound apolipoprotein A-I. Curr Opin Lipidol. 2006 Jun;17(3):214-20. |
37. Zabalawi M, Bharadwaj M, Horton H, Cline M, Willingham M, Thomas MJ, Sorci-Thomas MG. Inflammation and skin cholesterol in LDLr-/-, apoA-I-/- mice: link between cholesterol homeostasis and self-tolerance? J Lipid Res. 2007 Jan;48(1):52-65. |
38. Owen JS, Bharadwaj MS, Thomas MJ, Bhat S, Samuel MP, Sorci-Thomas MG. Ratio determination of plasma wild-type and L159R apoA-I using mass spectrometry: tools for studying apoA-IFin. J Lipid Res. 2007 Jan;48(1):226-34. |
39. Bhat S, Sorci-Thomas MG, Tuladhar R, Samuel MP, Thomas MJ. Conformational adaptation of apolipoprotein A-I to discretely sized phospholipid complexes. Biochemistry. 2007 Jul 03;46(26):7811-21. PMCID: PMC2553278 |
40. Thomas MJ, Bhat S, Sorci-Thomas MG. Three-dimensional models of HDL apoA-I: implications for its assembly and function. J Lipid Res. 2008 Sep;49(9):1875-83. PMCID: PMC2515525 |
41. Sorci-Thomas MG, Bhat S, Thomas MJ. Activation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices. Clin Lipidol. 2009 Feb;4(1):113-124. PMCID: PMC2891274 |
42. Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, Bharadwaj M, Walzem R, Chan L, Oka K, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):843-9. PMCID: PMC2761013 |
43. Bhat S, Sorci-Thomas MG, Calabresi L, Samuel MP, Thomas MJ. Conformation of dimeric apolipoprotein A-I milano on recombinant lipoprotein particles. Biochemistry. 2010 Jun 29;49(25):5213-24. PMCID: PMC2946800 |
44. Wang W, Xu H, Shi Y, Nandedkar S, Zhang H, Gao H, Feroah T, Weihrauch D, Schulte ML, Jones DW, Jarzembowski J, Sorci-Thomas M, Pritchard KA Jr. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res. 2010 Sep;51(9):2560-70. PMCID: PMC2918439 |
45. Wilhelm AJ, Zabalawi M, Owen JS, Shah D, Grayson JM, Major AS, Bhat S, Gibbs DP Jr, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J Biol Chem. 2010 Nov 12;285(46):36158-69. PMCID: PMC2975238 |
46. Potteaux S, Gautier EL, Hutchison SB, van Rooijen N, Rader DJ, Thomas MJ, Sorci-Thomas MG, Randolph GJ. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest. 2011 May;121(5):2025-36. PMCID: PMC3083793 |
47. Sorci-Thomas MG, Zabalawi M, Bharadwaj MS, Wilhelm AJ, Owen JS, Asztalos BF, Bhat S, Thomas MJ. Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice. Biochim Biophys Acta. 2012 Mar;1821(3):502-12. PMCID: PMC3690280 |
48. Sorci-Thomas MG, Owen JS, Fulp B, Bhat S, Zhu X, Parks JS, Shah D, Jerome WG, Gerelus M, Zabalawi M, Thomas MJ. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J Lipid Res. 2012 Sep;53(9):1890-909. PMCID: PMC3413229 |
49. Sorci-Thomas MG, Thomas MJ. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2561-5. PMCID: PMC3793253 |
50. Martel C, Li W, Fulp B, Platt AM, Gautier EL, Westerterp M, Bittman R, Tall AR, Chen SH, Thomas MJ, Kreisel D, Swartz MA, Sorci-Thomas MG, Randolph GJ. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest. 2013 Apr;123(4):1571-9. PMCID: PMC3613904 |
51. Sorci-Thomas MG, Thomas MJ. Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol. 2013 Sep;62(3):239-46. PMCID: PMC3772973 |
52. Pollard RD, Fulp B, Samuel MP, Sorci-Thomas MG, Thomas MJ. The conformation of lipid-free human apolipoprotein A-I in solution. Biochemistry. 2013 Dec 31;52(52):9470-81. PMCID: PMC3926756 |
53. Liu M, Seo J, Allegood J, Bi X, Zhu X, Boudyguina E, Gebre AK, Avni D, Shah D, Sorci-Thomas MG, Thomas MJ, Shelness GS, Spiegel S, Parks JS. Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein. J Biol Chem. 2014 Jan 31;289(5):2801-14. PMCID: PMC3908412 |
54. Gao M, Zhao D, Schouteden S, Sorci-Thomas MG, Van Veldhoven PP, Eggermont K, Liu G, Verfaillie CM, Feng Y. Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1900-9. PMCID: PMC4140992 |
55. Tavori H, Su YR, Yancey PG, Giunzioni I, Wilhelm AJ, Blakemore JL, Zabalawi M, Linton MF, Sorci-Thomas MG, Fazio S. Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL. J Lipid Res. 2015 Mar;56(3):635-643. PMCID: PMC4340310 |
56. Chadwick AC, Holme RL, Chen Y, Thomas MJ, Sorci-Thomas MG, Silverstein RL, Pritchard KA Jr, Sahoo D. Acrolein impairs the cholesterol transport functions of high density lipoproteins. PLoS One. 2015;10(4):e0123138. PMCID: PMC4388475 |
57. Pollard RD, Blesso CN, Zabalawi M, Fulp B, Gerelus M, Zhu X, Lyons EW, Nuradin N, Francone OL, Li XA, Sahoo D, Thomas MJ, Sorci-Thomas MG. Procollagen C-endopeptidase Enhancer Protein 2 (PCPE2) Reduces Atherosclerosis in Mice by Enhancing Scavenger Receptor Class B1 (SR-BI)-mediated High-density Lipoprotein (HDL)-Cholesteryl Ester Uptake. J Biol Chem. 2015 Jun 19;290(25):15496-15511. PMCID: PMC4505464 |
58. Thomas MJ, Sorci-Thomas MG. SAA: a link between cholesterol efflux capacity and inflammation? J Lipid Res. 2015 Aug;56(8):1383-5. PMCID: PMC4513981 |
59. Liu J, Lu H, Howatt DA, Balakrishnan A, Moorleghen JJ, Sorci-Thomas M, Cassis LA, Daugherty A. Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol. 2015 Aug;35(8):1826-34. PMCID: PMC4514578 |
60. Navratil AR, Vozenilek AE, Cardelli JA, Green JM, Thomas MJ, Sorci-Thomas MG, Orr AW, Woolard MD. Lipin-1 contributes to modified low-density lipoprotein-elicited macrophage pro-inflammatory responses. Atherosclerosis. 2015 Oct;242(2):424-32. PMCID: PMC4712446 |
61. Sorci-Thomas MG, Pollard RD, Thomas MJ. What does procollagen C-endopeptidase enhancer protein 2 have to do with HDL-cholesteryl ester uptake? Or how I learned to stop worrying and love reverse cholesterol transport? Curr Opin Lipidol. 2015 Oct;26(5):420-5. PMCID: PMC4564020 |
62. Sorci-Thomas MG, Thomas MJ. Microdomains, Inflammation, and Atherosclerosis. Circ Res. 2016 Feb 19;118(4):679-91. PMCID: PMC5291489 |
63. Cheng HY, Gaddis DE, Wu R, McSkimming C, Haynes LD, Taylor AM, McNamara CA, Sorci-Thomas M, Hedrick CC. Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. J Clin Invest. 2016 Sep 01;126(9):3236-46. PMCID: PMC5004951 |
64. Pollard RD, Fulp B, Sorci-Thomas MG, Thomas MJ. High-Density Lipoprotein Biogenesis: Defining the Domains Involved in Human Apolipoprotein A-I Lipidation. Biochemistry. 2016 Sep 06;55(35):4971-81. PMCID: PMC5356376 |
65. Kaul S, Xu H, Zabalawi M, Maruko E, Fulp BE, Bluemn T, Brzoza-Lewis KL, Gerelus M, Weerasekera R, Kallinger R, James R, Zhang YS, Thomas MJ, Sorci-Thomas MG. Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio. J Am Heart Assoc. 2016 Nov 07;5(11). PMCID: PMC5210328 |
66. Lee MH, Appleton KM, El-Shewy HM, Sorci-Thomas MG, Thomas MJ, Lopes-Virella MF, Luttrell LM, Hammad SM, Klein RL. S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization. J Lipid Res. 2017 Feb;58(2):325-338. PMCID: PMC5282949 |
67. Hoekstra M, Sorci-Thomas M. Rediscovering scavenger receptor type BI: surprising new roles for the HDL receptor. Curr Opin Lipidol. 2017 Jun;28(3):255-260. PMCID: PMC5523812 |
68. Sorci-Thomas MG, Thomas MJ. AIBP, NAXE, and Angiogenesis: What's in a Name? Circ Res. 2017 May 26;120(11):1690-1691. PMCID: PMC5497770 |
69. Sorci-Thomas MG, Thomas MJ. Anti-inflammatory liaisons: T regulatory cells and HDL. J Lipid Res. 2017 Aug;58(8):1491-1492. PMCID: PMC5538272 |
70. Williams JW, Elvington A, Ivanov S, Kessler S, Luehmann H, Baba O, Saunders BT, Kim KW, Johnson MW, Craft CS, Choi JH, Sorci-Thomas MG, Zinselmeyer BH, Brestoff JR, Liu Y, Randolph GJ. Thermoneutrality but Not UCP1 Deficiency Suppresses Monocyte Mobilization Into Blood. Circ Res. 2017 Sep 01;121(6):662-676. PMCID: PMC5718914 |
71. Melchior JT, Walker RG, Cooke AL, Morris J, Castleberry M, Thompson TB, Jones MK, Song HD, Rye KA, Oda MN, Sorci-Thomas MG, Thomas MJ, Heinecke JW, Mei X, Atkinson D, Segrest JP, Lund-Katz S, Phillips MC, Davidson WS. A consensus model of human apolipoprotein A-I in its monomeric and lipid-free state. Nat Struct Mol Biol. 2017 Dec;24(12):1093-1099. PMCID: PMC5749415 |
72. Milasan A, Jean G, Dallaire F, Tardif JC, Merhi Y, Sorci-Thomas M, Martel C. Apolipoprotein A-I Modulates Atherosclerosis Through Lymphatic Vessel-Dependent Mechanisms in Mice. J Am Heart Assoc. 2017 Sep 22;6(9). PMCID: PMC5634311 |
73. Favari E, Thomas MJ, Sorci-Thomas MG. High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis. J Cardiovasc Pharmacol. 2018 Jun;71(6):325-331. |
74. Gaddis DE, Padgett LE, Wu R, McSkimming C, Romines V, Taylor AM, McNamara CA, Kronenberg M, Crotty S, Thomas MJ, Sorci-Thomas MG, Hedrick CC. Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. Nat Commun. 2018 Mar 15;9(1):1095. PMCID: PMC5854619 |
75. Huang LH, Zinselmeyer BH, Chang CH, Saunders BT, Elvington A, Baba O, Broekelmann TJ, Qi L, Rueve JS, Swartz MA, Kim BS, Mecham RP, Wiig H, Thomas MJ, Sorci-Thomas MG, Randolph GJ. Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis. Cell Metab. 2019 Feb 05;29(2):475-487.e7. PMCID: PMC6365189 |
76. Ossoli A, Simonelli S, Varrenti M, Morici N, Oliva F, Stucchi M, Gomaraschi M, Strazzella A, Arnaboldi L, Thomas MJ, Sorci-Thomas MG, Corsini A, Veglia F, Franceschini G, Karathanasis SK, Calabresi L. Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome. Arterioscler Thromb Vasc Biol. 2019 May;39(5):915-924. |
77. Rodriguez A, Trigatti BL, Mineo C, Knaack D, Wilkins JT, Sahoo D, Asztalos BF, Mora S, Cuchel M, Pownall HJ, Rosales C, Bernatchez P, Ribeiro Martins da Silva A, Getz GS, Barber JL, Shearer GC, Zivkovic AM, Tietge UJF, Sacks FM, Connelly MA, Oda MN, Davidson WS, Sorci-Thomas MG, Vaisar T, Ruotolo G, Vickers KC, Martel C. Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop: Focus on Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019 Dec;39(12):2457-2467. PMCID: PMC6937204 |
78. Ouweneel AB, Thomas MJ, Sorci-Thomas MG. The ins and outs of lipid rafts: functions in intracellular cholesterol homeostasis, microparticles, and cell membranes. J Lipid Res. 2020 05;61(5):676-686. PMCID: PMC7193959 |
79. Li Z, Votava JA, Zajac GJM, Nguyen JN, Leyva Jaimes FB, Ly SM, Brinkman JA, De Giorgi M, Kaul S, Green CL, St Clair SL, Belisle SL, Rios JM, Nelson DW, Sorci-Thomas MG, Lagor WR, Lamming DW, Eric Yen CL, Parks BW. Integrating Mouse and Human Genetic Data to Move beyond GWAS and Identify Causal Genes in Cholesterol Metabolism. Cell Metab. 2020 Apr 07;31(4):741-754.e5. PMCID: PMC7184639 |
80. Thomas MJ, Sorci-Thomas MG. Linking Lipid-Related Transcription and Cardiovascular Disease Through GWAS. Circ Res. 2020 Nov 06;127(11):1362-1364. PMCID: PMC7653958 |
81. Singh B, Kosuru R, Lakshmikanthan S, Sorci-Thomas MG, Zhang DX, Sparapani R, Vasquez-Vivar J, Chrzanowska M. Endothelial Rap1 (Ras-Association Proximate 1) Restricts Inflammatory Signaling to Protect From the Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):638-650. PMCID: PMC8105264 |
82. Ouweneel AB, Thomas MJ, Sorci-Thomas MG. The ins and outs of lipid rafts: functions in intracellular cholesterol homeostasis, microparticles, and cell membranes: Thematic Review Series: Biology of Lipid Rafts. J Lipid Res. 2020 May;61(5):676-686. PMCID: PMC7193959 |
83. Han YH, Onufer EJ, Huang LH, Sprung RW, Davidson WS, Czepielewski RS, Wohltmann M, Sorci-Thomas MG, Warner BW, Randolph GJ. Enterically derived high-density lipoprotein restrains liver injury through the portal vein Science. 23 July 2021;373(6553). |
84. Neu SD, Strzepa A, Martin D, Sorci-Thomas MG, Pritchard KA, Dittel BN. Myeloperoxidase inhibition ameliorates plaque psoriasis in mice Antioxidants. September 2021;10(9). |
85. Han YH, Onufer EJ, Huang LH, Sprung RW, Davidson WS, Czepielewski RS, Wohltmann M, Sorci-Thomas MG, Warner BW, Randolph GJ. Enterically derived high-density lipoprotein restrains liver injury through the portal vein. Science. 2021 Jul 23;373(6553). PMCID: PMC8478306 |
86. Hafiane A, Gianopoulos I, Sorci-Thomas MG, Daskalopoulou SS. Current models of apolipoprotein A-I lipidation by adenosine triphosphate binding cassette transporter A1. Curr Opin Lipidol. 2022 Apr 01;33(2):139-145. |
87. Neu SD, Strzepa A, Martin D, Sorci-Thomas MG, Pritchard KA Jr, Dittel BN. Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice. Antioxidants (Basel). 2021 Aug 25;10(9). PMCID: PMC8472607 |
88. Xu H, Thomas MJ, Kaul S, Kallinger R, Ouweneel AB, Maruko E, Oussaada SM, Jongejan A, Cense HA, Nieuwdorp M, Serlie MJ, Goldberg IJ, Civelek M, Parks BW, Lusis AJ, Knaack D, Schill RL, May SC, Reho JJ, Grobe JL, Gantner B, Sahoo D, Sorci-Thomas MG. Pcpe2, a Novel Extracellular Matrix Protein, Regulates Adipocyte SR-BI-Mediated High-Density Lipoprotein Uptake. Arterioscler Thromb Vasc Biol. 2021 Nov;41(11):2708-2725. PMCID: PMC8551036 |
89. Hafiane A, Gianopoulos I, Sorci-Thomas MG, Daskalopoulou SS. Apolipoprotein A-I carboxy-terminal domain residues 187-243 are required for adiponectin-induced cholesterol efflux. Cell Signal. 2022 Mar;91:110222. |
90. Vachon L, Smaani A, Tessier N, Jean G, Demers A, Milasan A, Ardo N, Jarry S, Villeneuve L, Alikashani A, Finherty V, Ruiz M, Sorci-Thomas MG, Mayer G, Martel C. Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids Theranostics. 2022;12(3):1440-1458. |
91. Vachon L, Smaani A, Tessier N, Jean G, Demers A, Milasan A, Ardo N, Jarry S, Villeneuve L, Alikashani A, Finherty V, Ruiz M, Sorci-Thomas MG, Mayer G, Martel C. Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids. Theranostics. 2022;12(3):1440-1458. PMCID: PMC8771568 |
92. Knaack DA, Sorci-Thomas MG, Thomas MJ, Chen Y, Sahoo D. Regulation of Adipocyte Metabolic Homeostasis by SR-BI and PCPE2. FASEB J. 2022 May;36 Suppl 1. |
93. Natarajan R, Moore K, Sahoo D, Nana-Sinkam P, Fowler AAB 3rd, Sime P, Sorci-Thomas M, Aikawa E, ATVB Council, friends, and colleagues. Shobha Ghosh (1958-2021). Arterioscler Thromb Vasc Biol. 2022 Mar;42(3):239-240. |
94. Wacker BK, Bi L, Liu L, Sorci-Thomas MG, Ng P, Palmer DJ, Tang C, Dichek DA. N-terminal eGFP-tagging of rabbit apolipoprotein A-I decreases expression and impairs cholesterol-efflux activity. Biochim Biophys Acta Mol Cell Biol Lipids. 2023 May;1868(5):159301. PMCID: PMC10127936 |
95. Schmidt AM, Sorci-Thomas MG, Chen Y, Hegele RA. Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies. Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1093-1095. PMCID: PMC10330751 |
96. Mo ZW, Peng YM, Zhang YX, Li Y, Kang BA, Chen YT, Li L, Sorci-Thomas MG, Lin YJ, Cao Y, Chen S, Liu ZL, Gao JJ, Huang ZP, Zhou JG, Wang M, Chang GQ, Deng MJ, Liu YJ, Ma ZS, Hu ZJ, Dong YG, Ou ZJ, Ou JS. High-density lipoprotein regulates angiogenesis by long non-coding RNA HDRACA. Signal Transduct Target Ther. 2023 Aug 14;8(1):299. PMCID: PMC10423722 |
97. Dai W, Zhang H, Lund H, Zhang Z, Castleberry M, Rodriguez M, Kuriakose G, Gupta S, Lewandowska M, Powers HR, Valmiki S, Zhu J, Shapiro AD, Hussain MM, López JA, Sorci-Thomas MG, Silverstein RL, Ginsberg HN, Sahoo D, Tabas I, Zheng Z. Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes. Science. 2023 Sep;381(6661):eadh5207. PMCID: PMC10697821 |
98. Knaack DA, Chang J, Thomas MJ, Sorci-Thomas MG, Chen Y, Sahoo D. Scavenger receptor class B type I is required for efficient glucose uptake and metabolic homeostasis in adipocytes. bioRxiv. 2023 Aug 22. PMCID: PMC10473602 |
99. Nagesh PT, Nishi H, Rawal S, Zahr T, Miano JM, Sorci-Thomas M, Xu H, Akbar N, Choudhury RP, Misra A, Fisher EA. HDL regulates TGFß-receptor lipid raft partitioning, restoring contractile features of cholesterol-loaded vascular smooth muscle cells. bioRxiv. 2023 Oct 19. PMCID: PMC10614922 |
100. Sorci-Thomas MG, Hegele RA, Remaley AT. A Century of Milestones and Breakthroughs Related to Low- and High-Density Lipoproteins. Arterioscler Thromb Vasc Biol. 2024 Jan;44(1):7-11. PMCID: PMC10760802 |
